Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Single Ascending Dose Study
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental |
| |
| 2 | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD7268 | Drug | Solution/Capsule, Oral, once daily |
| |
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| To assess the safety and tolerability of single ascending dose administration of AZD7268 when given orally to healthy male subjects and female subjects of non-childbearing potential. | Safety assessments are made at each visit, at least daily, during the study. |
| Measure | Description | Time Frame |
|---|---|---|
| To characterize the pharmacokinetics of AZD7268 in plasma and urine. | Blood and urine samples will be taken during the study. | |
| To assess the effect of food on the safety and pharmacokinetic profile of AZD7268. | Safety assessments and blood and urine samples will be taken throughout the study. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sylvan Hurewitz, M.D. | AstraZeneca Clinical Pharmacology Unit, US | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Philadelphia | Pennsylvania | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|